Impact1 at Stanford Biodesign

Each year, the US Food and Drug Administration (FDA) approves far fewer health technologies for use in children than adults. This means that pediatric specialists do not always have access to the advanced tools they need to address the unique healthcare needs of their small, vulnerable patients. Stanford launched Impact1 to improve the health, safety, and quality of life of pediatric patients and pregnant women. We do this by accelerating the development and availability of high-value, high-impact pediatric health technologies. The program leverages Stanford Biodesign’s need-driven innovation process to accomplish this goal. It benefits from access to world-renowned clinicians and engineers at Stanford, as well as an unparalleled network of Silicon Valley experts in medical device product development, regulatory affairs, intellectual property, reimbursement, and commercialization. Our team also represents the Stanford collaborators of the UCSF-Stanford Pediatric Device Consortium.